Terbinafine hepatotoxicity: case report and review of the literature.
We report a patient who developed significant liver dysfunction following therapy with terbinafine. At the end of a 3 1/2-wk course of terbinafine, he developed progressive jaundice and pruritus. His serum bilirubin peaked at 30.9 mg/dl 3 wk after discontinuing terbinafine. A liver biopsy revealed mild to moderate mixed cellular infiltrate in the portal tracts, and hepatocellular and canicular cholestasis. His liver tests normalized 100 days after stopping terbinafine.
Fernandes
N F
NF
Center for Liver Diseases and Transplantation and Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA.
Geller
S A
SA
Fong
T L
TL
D000328:Adult; D000935:Antifungal Agents / Q000009:adverse effects*; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury; D006801:Humans; D008107:Liver Diseases / Q000473:pathology; D008297:Male; D009281:Naphthalenes / Q000009:adverse effects*; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine